Eribulin

HALAVEN®

About HALAVEN®

  1. Marketed by Eisai Inc.
  2. Microtubule dynamics inhibitor
  3. Treatment of refractory, metastatic breast cancer and liposarcoma

Approvals

  1. First U.S. approval: November 15, 2010
  2. First E.U. approval: March 17, 2011

Constraint date forecast:

  1. Patent expiry: 2023 (United States)
  2. SPC expiry: 2024 (European Union)
  3. Patent expiry: 2024 (Japan)

API availability

Source: Cortellis Generics Intelligence

The future of the generics landscape

Drugs to Watch

XARELTO®

Rivaroxaban, Rivaroxaban

心血管疾病

From innovation to bottom line

Access our global intelligence, advanced analytics and global team of experts.

Contact our team